Objective: Fingerprint and anti-tumor pharmacodynamic analysis were used to probe the similarity of the principal pharmacodynamic components of Arisaema peninsulae and A. amurense

providing data support for the rational clinical use of A. peninsulae. Method: High performance liquid chromatography (HPLC) method was used to establish the fingerprint of 11 batches of A. peninsulae and A. amurense from different origins or harvest time points. Thiazolyl blue(MTT) assay was used to investigate their inhibition effect on SMMC-7721 cells proliferation. Grey relational analysis and partial least-squares regression analysis methods were used to analyze the spectrum-activity relationship of 6 batches of A. peninsulae and 5 batches of A. amurense respectively

aimed to find the ingredients with greater contribution to efficacy and evaluate the similarities. Result: The fingerprint of 11 batches of A. peninsulae and A. amurense from different origins or harvest time points was established

and their anti-tumor activity was verified. Grey relational analysis results showed that 12 components from 15 components of A. peninsulae whose pharmacodynamic correlation coefficient was greater than 0.80 were the same as A. amurense. And the rationality of the grey relational analysis results was verified by partial least-squares regression analysis. The comprehensive analysis proved that A. peninsulae had a good similarity with A. amurense based on the main pharmacodynamic components. Conclusion: Guided by the anti-tumor efficacy

this experiment verified the similarity of chemical compositions between A. peninsulae and A. amurense

providing reasonable basis for the use of A. peninsulae

and providing experimental basis for its quality control.